Coya Therapeutics, Inc. COYA
Coya Therapeutics, Inc. (Nasdaq: COYA) is a CNS/neurology/psychiatry drug developer. Its lead program, COYA 302 (low-dose IL-2 + CTLA4-Ig), is in Phase 2 for Amyotrophic lateral sclerosis (ALS).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| COYA 302 - ALSTARS | ALS | protein/peptide | Phase 2 |
| COYA 302 - FTD | Frontotemporal dementia | protein/peptide | Phase 1 |
| COYA 201 / COYA 206 (Treg-derived exosomes) | — | biologic-other | Pre-clinical |
| COYA 303 | — | protein/peptide | Pre-clinical |
Recent results and decisions
- Aug 11, 2026n/a FDA granted Fast Track Designation to COYA 302 for ALS.
Received FDA Fast Track Designation for COYA 302 for the treatment of ALS.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.